Biogen (BIIB) receives a hold rating as Leqembi sales may begin to sag, although it is possible new drug approvals may make up some of the difference. Eisai's claim that Leqembi delays the progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback